Purification of partially resolved enantiomeric mixtures with the guidance of ternary phase diagram

被引：22

作者：

Chen, Alex M. ^{[1
]}

Wang, Yaling ^{[2
]}

Wenslow, Robert M. ^{[1
]}

机构：

[1] Merck & Co Inc, Ctr Mat Sci & Engn, Rahway, NJ 07065 USA

[2] Merck & Co Inc, Proc Res, Rahway, NJ 07065 USA

来源：

ORGANIC PROCESS RESEARCH & DEVELOPMENT | 2008年 / 12卷 / 02期

关键词：

D O I：

10.1021/op7002387

中图分类号：

O69 [应用化学];

学科分类号：

081704 ;

摘要：

The rationale and strategy for purification of partially resolved enantiomeric mixtures based on ternary phase diagrams are discussed. From the ternary phase diagram, one can deduce if a feasible process can be developed to upgrade the enantiomeric excess (ee) of a partially resolved enantiomeric mixture. When such a process is determined to be feasible, the optimal conditions can then be defined based on the ternary phase diagram to upgrade ee to a desirable value with maximum yield. Three ee upgrade examples of pharmaceutical processes are presented to demonstrate the importance and success of application of ternary phase diagrams in designing an optimal process.

引用

页码：271 / 281

页数：11

共 18 条

[1]

CASY AF, 1970, MED CHEM, V1, P81

[2] Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans [J].

Cheng, K ;

Wu, TJ ;

Wu, KK ;

Sturino, C ;

Metters, K ;

Gottesdiener, K ;

Wright, SD ;

Wang, ZY ;

O'Neill, G ;

Lai, E ;

Waters, MG .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (17) :6682-6687

[3]

Collins A.N., 1992, CHIRALITY IND COMMER

[4] Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses [J].

Herman, GA ;

Stevens, C ;

Van Dyck, K ;

Bergman, A ;

Yi, BM ;

De Smet, M ;

Snyder, E ;

Hilliard, D ;

Tanen, M ;

Tanaka, W ;

Wang, AQ ;

Zeng, W ;

Musson, D ;

Winchell, G ;

Davies, MJ ;

Ramael, S ;

Gottesdiener, KM ;

Wagner, JA .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (06) :675-688

[5]

INAGAKI M, 1977, CHEM PHARM BULL, V25, P2497

[6]

Jacques J., 1981, Enantiomers, Racemates and Resolutions

[7] Rationalization and prediction of solution enantiomeric excess in ternary phase systems [J].

Klussmann, Martin ;

White, Andrew J. R. ;

Armstrong, Alan ;

Blackmond, Donna G. .

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2006, 45 (47) :7985-7989

[8]

KOGA K, 1995, NEW METHODS DRUGS RE, V4, P25

[9] Discovery of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity [J].

Lin, Linus S. ;

Lanza, Thomas J., Jr. ;

Jewell, James P. ;

Liu, Ping ;

Shah, Shrenik K. ;

Qi, Hongbo ;

Tong, Xinchun ;

Wang, Junying ;

Xu, Suoyu S. ;

Fong, Tung M. ;

Shen, Chun-Pyn ;

Lao, Julie ;

Xiao, Jing Chen ;

Shearman, Lauren P. ;

Stribling, D. Sloan ;

Rosko, Kimberly ;

Strack, Alison ;

Marsh, Donald J. ;

Feng, Yue ;

Kumar, Sanjeev ;

Samuel, Koppara ;

Yin, Wenji ;

Van der Ploeg, Lex H. T. ;

Goulet, Mark T. ;

Hagmann, William K. .

JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (26) :7584-7587

[10] Binary and ternary phase diagrams of two enantiomers in solvent systems [J].

Lorenz, H ;

Seidel-Morgenstern, A .

THERMOCHIMICA ACTA, 2002, 382 (1-2) :129-142

← 1 2 →